NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016

Carroll, Peter R.; Parsons, J. Kellogg; Andriole, Gerald; Bahnson, Robert R.; Castle, Erik P.; Catàlona, William J.; Dahl, Douglas M.; Davis, John W.; Epstein, Jonathan I.; Etzioni, Ruth; Farrington, Thomas; Hemstreet, George P.; Kawachi, Mark H.; Kim, Simon; Lange, Paul H.; Loughlin, Kevin R.; Lowrance, William T.; Maroni, Paul; Mohler, James L.; Morgan, Todd M.; Moses, Kelvin A.; Nadler, Robert B.; Poch, Michael; Scales, Chuck; Shaneyfelt, Terrence; Smaldone, Marc C.; Sonn, Geoffrey A.; Sprenkle, Preston; Vickers, Andrew; Wake, Robert; Shead, Dorothy A.; Freedman-Cass, Deborah A.

doi:10.6004/jnccn.2016.0060

Cited by 285 publications

(275 citation statements)

References 67 publications

Supporting

Mentioning

257

Contrasting

Unclassified

Order By: Relevance

“…The criteria for men to undergo prostate biopsy include prostate-specific antigen (PSA) >4 ng/mL and/or positive digital rectal examination (DRE) [3]. Because of low sensitivity of ultrasound to prostate tumor, ultrasound-guided prostate biopsies are generally mapping all around the prostate without targets [4].…”

Section: Introductionmentioning

confidence: 99%

Significance of MRI/Transrectal Ultrasound Fusion Three-Dimensional Model-Guided, Targeted Biopsy Based on Transrectal Ultrasound-Guided Systematic Biopsy in Prostate Cancer Detection: A Systematic Review and Meta-Analysis

Tang¹,

Liu²,

Tang³

et al. 2017

Urol Int

View full text Add to dashboard Cite

Purpose: To assess MRI/Transrectal Ultrasound (TRUS) fusion three-dimensional model-guided targeted biopsy (3D-Tb) versus TRUS-guided systematic biopsy (Sb) in detecting overall and high-Gleason-score (≥7) prostate cancer (PCa). Methods: Pubmed and Web of science were searched. Studies with men having a suspicious lesion on MRI were included, which were divided into initial biopsy, previous negative biopsy, and mixed groups in meta-analysis. Results: Totally 13 cohorts in 12 studies, with 3,225 men were included. In total population, 3D-Tb and Sb did not differ significantly in the PCa detection rate (43.1 vs. 42.6%, p = 0.36), but after excluding initial biopsy group, the superiority of 3D-Tb became significant (p = 0.01); 3D-Tb had a significantly higher detection rate of high-Gleason-score PCa compared to Sb (30.0 vs. 24.1%, p < 0.05); 3D-Tb plus Sb significantly improved the PCa detection rate based on Sb alone (52.7 vs. 42.6%, p < 0.05). Conclusions: In men with increased serum PSA and/or abnormal DRE and suspicious lesion on MRI but non-previous evidence of PCa, 3D-Tb plus Sb improves the PCa detection rate based on Sb alone. 3D-Tb alone has better performance in detecting high-Gleason-score PCa, and tends to have a higher PCa detection rate in population with previous negative biopsy compared to Sb.

show abstract

Section: Introductionmentioning

confidence: 99%

Significance of MRI/Transrectal Ultrasound Fusion Three-Dimensional Model-Guided, Targeted Biopsy Based on Transrectal Ultrasound-Guided Systematic Biopsy in Prostate Cancer Detection: A Systematic Review and Meta-Analysis

Tang¹,

Liu²,

Tang³

et al. 2017

Urol Int

View full text Add to dashboard Cite

show abstract

“…[36][37][38] An algorithm has been suggested to identify high-risk patients based on their family history, digital rectal examination results and ethnicity. 39 In the current study, while the overall mortality trend was found to have increased over the study period, there was a reduction in certain years, perhaps due to inconsistencies in the data collection. Temporarily rising trends may be due to the improved reporting and registration of deaths.…”

Section: Resultsmentioning

confidence: 46%

Mortality Rate and Years of Life Lost Due to Prostate Cancer in Yazd Province, Iran: A 10-year study

Mirzaei

Mirzadeh

Mehrara

2018

Sultan Qaboos Univ Med J

View full text Add to dashboard Cite

abstract:Objectives: Prostate cancer is a leading cause of cancer-related deaths. The number of deaths and years of life lost (YLL) due to a disease can be used to monitor health status, assess healthcare needs and determine the prioritisation and allocation of health resources within a population; in addition, the latter calculation can serve as a baseline indicator of premature mortality. This study aimed to measure prostate cancer-related mortality and YLL in Yazd Province, Iran. Methods: This study included all prostate cancer-related deaths in Yazd Province reported between March 2001 and March 2010. Mortality data were obtained from a provincial death registration system which integrates data from different sources. YLL was calculated based on an individual's age at death and their life expectancy according to age group. Results: During the study period, prostate cancer was the fourth most common fatal cancer among men, resulting in 324 deaths or 10.0% of all cancer-related deaths. The crude mortality rate per 100,000 individuals increased from 4.7 in 2001 to 8.8 in 2010. Premature deaths caused 1,358.7 YLL and the YLL caused by prostate cancer deaths more than doubled from 94.7 in 2001 to 196.5 in 2010. Conclusion: Due to changes in population structure, it is likely that the burden of prostate cancer will continue to increase in Yazd Province. As such, it is necessary that the national health system implements screening programmes and improves public awareness of prostate cancer-associated risk factors. Keywords

show abstract

“…The NCCN guidelines do acknowledge that although mpMRI prior to initial biopsy is not routinely recommended, there is a growing body of evidence outlining its possible benefit and hint that a formal recommendation is imminent [30]. The EAU guidelines panel recently published a meta-analysis examining the NPV of mpMRI prior to initial biopsy and concluded that although there is potential for the test to be used as a triage for biopsy, it is still not sufficiently accurate at the present [31].…”

Section: Current Guideline Recommendationsmentioning

confidence: 99%

The Use of Magnetic Resonance Imaging in the Prostate Cancer Primary Diagnostic Pathway: Is It Ready for Primetime?

Sathianathen

Warlick

2018

World J Mens Health

View full text Add to dashboard Cite

Multiparametric magnetic resonance imaging (mpMRI) has been increasingly utilized in the prostate cancer diagnostic landscape over the last five years. The majority of the literature has focused on its use in men with a previous negative biopsy. However, over time, clinicians have begun using mpMRI in the work-up of men being considered for primary biopsy and subsequently data characterizing its diagnostic performance in this setting is emerging. This review comprehensively assesses the utility of mpMRI in the primary biopsy setting.

show abstract

NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016

Cited by 285 publications

References 67 publications

Significance of MRI/Transrectal Ultrasound Fusion Three-Dimensional Model-Guided, Targeted Biopsy Based on Transrectal Ultrasound-Guided Systematic Biopsy in Prostate Cancer Detection: A Systematic Review and Meta-Analysis

Significance of MRI/Transrectal Ultrasound Fusion Three-Dimensional Model-Guided, Targeted Biopsy Based on Transrectal Ultrasound-Guided Systematic Biopsy in Prostate Cancer Detection: A Systematic Review and Meta-Analysis

Mortality Rate and Years of Life Lost Due to Prostate Cancer in Yazd Province, Iran: A 10-year study

The Use of Magnetic Resonance Imaging in the Prostate Cancer Primary Diagnostic Pathway: Is It Ready for Primetime?

Contact Info

Product

Resources

About